Click here to view online. Add this email to your safelist.
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
24 August 2017
New sub-analysis to be presented at the European Society of Cardiology (ESC) congress provides additional evidence of cardiovascular (CV) benefits associated with longer-term use of Brilinta
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
